leisure time -WSS

leisure time

author：entertainment 2025-09-05 09:20:21 - browse：1964

STAT's Damian Garde speaks with Mikael Dolsten and Mathai Mammen, in New York on March 21, 2024 — From left to right, STAT's Damian Garde; Mikael Dolsten, chief scientific officer of Pfizer research and development; and Rose Loughlin, Moderna’s senior vice president of early research and development, discuss the future of pharma at the STAT 2024 Breakthrough Summit East. STAT

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday.

“We used to say, well, you may spend five years in the research phase, another five in development. Now I see a project that takes one year of research, from an idea to studies,” said Mikael Dolsten, chief scientific officer and president of Pfizer research and development. “Time is life. You care about patients. And when the distance to run is long, it holds back the energy and the inspiration.”

Key to that success are transformative new technologies like messenger RNA, which powered vaccines developed by Pfizer with its partner BioNTech.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： How doctors and nurses shape Google's AI

leisure time

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Teladoc has a new CEO, but challenges remain the same

STAT Readout: Today's biotech news includes Sana and Amylyx

European regulators recommend Amylyx's ALS drug be rejected

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Coercive sterilizations revealed by STAT prompt outrage

knowledge

leisure time

hotspot

Bright Health sells Medicare Advantage business to Molina

Stephen Quake on the Chan Zuckerberg quest to conquer disease

BioMarin wins approval for gene therapy to treat hemophilia A

The system is set up to fail children with medical complexity

BioMarin wins approval for gene therapy to treat hemophilia A

How clinical AI models' predictive power can degrade over time

Medical records are filled with copy

STAT Readout Newsletter: Today in biotech, life science news

Malaria cases in Florida and Texas: Here’s what you need to know

European regulators recommend Amylyx's ALS drug be rejected

leisure time

How clinical AI models' predictive power can degrade over time

ALS patient reclaims some autonomy thanks to wearable 'robot'

Statins may not be needed by millions of people, study suggests

Coercive sterilizations revealed by STAT prompt outrage

Takeaways from AdvaMed, the largest medical devices conference

Cheap, fast test for Zika and dengue could cost just $1

hotspot

leisure time

leisure time

focus